News | February 07, 2025
Akums reports Q3 FY25 adjusted PAT at Rs. 66.3 Cr
Branded formulation business continues to perform well across domestic and export markets
Branded formulation business continues to perform well across domestic and export markets
These results represent critical milestones for Philogen, as Fibromun has the potential to become second product to successfully complete multinational clinical trials with registration potential
Dyrupeg will be available as 6 mg solution for injection in prefilled syringe and is intended for the reduction in the duration of neutropenia
Such combined efficacy (achieving clinical cure and microbiologic cure) of Zaynich is highest ever among all the FDA-approved novel antibiotics developed in the last more than 10 years
Recommendation based on results of Phase 3 CheckMate -9DW clinical trial demonstrating statistically significant and clinically meaningful improvement in overall survival with Opdivo plus Yervoy compared to investigator’s choice of lenvatinib or sorafenib in this patient population
The new facility, which has a capacity of 5,000 metric tonnes, will manufacture nutraceuticals and dietary-active ingredients for human consumption.
The group reported Q3FY25 operating revenue of Rs 3,821 crore, driven by sustained double-digit growth of 14 per cent in biosimilars
Teriflunomide is a novel disease-modifying agent that was approved for use in the treatment of multiple sclerosis
EBITDA margins expand to 31.3%
The company is committed to unlocking new frontiers in neuroscience and developing Usnoflast for patients with ALS
Subscribe To Our Newsletter & Stay Updated
